
Claims

1. The use of ~~A method of treating a sleep disorder; said method comprising administering to a subject in need thereof an effective amount of~~ daridorexant:



in free or pharmaceutically acceptable salt form;
in the manufacture of a medicament for the treatment of a sleep disorder;
wherein ~~daridorexant~~ said medicament improves the daytime performance of the subject to whom it is administered ~~of said subject~~.

2. The use~~The method~~ according to claim 1, wherein said improvement of daytime performance ~~of said subject~~ is assessed by at least one of:

- the IDSIQ daytime alert/cognition domain score; and/or
- the IDSIQ daytime mood domain score, and/or
- the IDSIQ daytime sleepiness domain score.

3. The use~~A method of treating a sleep disorder; said method comprising administering to a subject in need thereof an effective amount~~ of daridorexant in free or pharmaceutically acceptable salt form; in the manufacture of a medicament for the treatment of a sleep disorder;
wherein ~~daridorexant~~ said medicament reduces daytime clinical manifestations associated with said sleep disorder.

4. The use ~~The method~~ according to claim 3, wherein said daytime clinical manifestations associated with said sleep disorder are symptoms of daytime sleepiness, especially as assessed by the IDSIQ daytime sleepiness domain score.

5. The use ~~The method~~ according to any one of claims 1 to 4, wherein said improvement of daytime performance / reduction of daytime clinical manifestations associated with said sleep disorder is expressed by subjects to whom daridorexant has been administered, wherein said subjects feel, cumulatively, less physically tired, less mentally tired, less sleepy and more energetic during the day.

6. The use ~~The method~~ according to any one of claims 1 to 5, wherein said sleep disorder is a dyssomnia or a sleep disorder associated with a general medical condition.

7. The use ~~The method~~ according to any one of claims 1 to 5, wherein said sleep disorder is an insomnia.

8. The use ~~The method~~ according to any one of claims 1 to 7, wherein said treatment of said sleep disorder results in at least one, preferably all of the following treatment effects:

- a decrease in latency to persistent sleep (LPS); and/or
- a decrease in wake time after sleep onset (WASO); and/or
- an increase in total sleep time subjectively (sTST) assessed daily by the patient.

9. The use ~~The method~~ according to any one of claims 1 to 8, wherein said medicament is intended for a subject who has been diagnosed as having difficulties with sleep onset and/or sleep maintenance.

10. The use ~~The method~~ according to any one of claims 1 to 9, wherein said medicament comprises daridorexant in free or pharmaceutically acceptable salt form~~, is administered~~ in a unit dose of about 25 mg of daridorexant, or in a unit dose of about 50 mg of daridorexant.

11. The use ~~The method~~ according to any one of claims 1 to 10, wherein ~~the~~ daridorexant is in hydrochloric acid salt form.

12. The use ~~The method~~ according to any one of claims 1 to 11, wherein said medicament ~~daridorexant in free or pharmaceutically acceptable salt form is administered~~ is in form of a tablet; wherein said tablet is a film coated tablet comprising

- a tablet core; said tablet core comprising at least two, preferably all of the following excipients: mannitol, microcrystalline cellulose, povidone, croscarmellose sodium, silicon dioxide, and/or magnesium stearate; and
- a film coat; said film coat comprising at least two, preferably all of the following excipients: hypromellose, microcrystalline cellulose, glycerine, talc, titanium dioxide, and/or iron oxide.

13. The use ~~The method~~ according to any one of claims 1 to 12, wherein ~~daridorexant in free or pharmaceutically acceptable salt form is administered once daily~~ said medicament is to be administered within 1 h before bedtime, in particular within 30 min before bedtime.

14. The use ~~The method~~ according to any one of claims 1 to 13, wherein said sleep disorder is a chronic sleep disorder.

15. The use of daridorexant in free or pharmaceutically acceptable salt form in the preparation of a medicament wherein said medicament is for the treatment of ~~A method of treating~~ daytime sleepiness in a subject, ~~comprising administering to said subject an effective amount of daridorexant in free or pharmaceutically acceptable salt form~~, wherein said subject has a reduction in daytime sleepiness as assessed by the IDSIQ daytime sleepiness domain score; wherein especially said subject has been diagnosed as having a sleep disorder.

16. The use of daridorexant in free or pharmaceutically acceptable salt form in the preparation of a medicament for the treatment of an ~~A method of treating~~ insomnia ~~to~~ wherein said medicament improves sleep and daytime functioning, ~~comprising administering to a subject in need thereof an effective amount of daridorexant in free or~~

~~pharmaceutically acceptable salt form,~~ wherein notably said ~~subject has a reduction in~~medicament reduces daytime sleepiness as assessed by the IDSIQ daytime sleepiness domain score.

~~17. Daridorexant in free or pharmaceutically acceptable salt form for use in a method according to any one of claims 1 to 16.~~

5